Price History

Hover for the daily close. The dotted line marks the period open.

Compare OLMA with… →

OLMA Key Statistics

As of Sep 4, 2026

Trading

Open: $10.61
Previous Close: $10.73
Day's Range: 10.57–10.85
52-Week Range: 6.65–36.26
Volume: 505.30K
Beta: 1.99

Valuation

Market Cap: $940.60M
P/E Ratio: unprofitable
EPS (ttm): −2.12

Financials (FY)

Revenue (FY): $0.00
Net Income (FY): −$162.45M
Profit margin: 0.00%
Shares Outstanding: 87.50M
1-Year Return: +69.29%

Dividend and dates

Earnings Date: November 9, 2026estimated
Avg Volume: 1.31M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

OLMA Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

−1.88%−80.53%−73.82%+472.65%−58.45%+328.82%−57.00%

2020*202120222023202420252026*

Year	Return
2026 (partial year)	−57.00%
2025	+328.82%
2024	−58.45%
2023	+472.65%
2022	−73.82%
2021	−80.53%
2020 (partial year)	−1.88%

As of September 4, 2026.

OLMA Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$0.00	−$162.45M	—
2024	$0.00	−$129.47M	—
2023	$0.00	−$96.66M	—
2022	$0.00	−$104.79M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$0.00	—	−$178.70M	−$162.45M	—
2024	$0.00	—	−$142.26M	−$129.47M	—
2023	$0.00	—	−$104.96M	−$96.66M	—
2022	$0.00	—	−$106.99M	−$104.79M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

OLMA Valuation vs Biotechnology Median

Median of 656 stocks

Metric	OLMA	Biotechnology median	vs median
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Olema Pharmaceuticals, Inc. (OLMA) at $940.60M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 150.

Over the past 52 weeks the price has ranged from $6.65 to $36.26. OLMA last closed at $10.75 on September 4, 2026. That is +$0.02 (+0.19%) against the previous close. The latest close sits 61.65% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $162.45M. Profit margin runs at 0%. Trailing earnings per share are −2.12.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

The trailing one-year price return is +69.29%. Across 5 years the annualized return works out at −18.24%. Beta against the wider market is reported at 1.99. Daily returns over the trailing 5 years annualize to a volatility of 107.91%.

Growth & Income

No dividend is on file for OLMA.

2026 is still running; the price is −57.00% year to date. Across the complete calendar years on file, 2023 returned +472.65% and 2021 returned −80.53%. Of the 5 complete calendar years on file, 2 finished higher.

Peer Comparison

Olema Pharmaceuticals, Inc. (OLMA) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Olema Pharmaceuticals, Inc.	OLMA	$940.60M	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. Olema Pharmaceuticals, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Olema Pharmaceuticals, Inc.

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, a mechanistic target of rapamycin inhibitor, and a CDK4 inhibitor that is in Phase 1b/2 clinical trial for the treatment of ER+/HER2- advanced or metastatic breast cancer. It also develops OP-3136, an orally-available small molecule that potently and selectively inhibits KAT6 which is in Phase 1 clinical trials for patients with breast and other solid tumor cancers. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Visit website →

Olema Pharmaceuticals, Inc. (OLMA) Stock Analysis